102 related articles for article (PubMed ID: 11243192)
1. [The solid-phase synthesis of methotrexate-alpha-peptides].
Shi PT; Hao XK; Chen Y; Zhang YH; Tao QY
Yao Xue Xue Bao; 1997; 32(2):106-9. PubMed ID: 11243192
[TBL] [Abstract][Full Text] [Related]
2. Methotrexate-alpha-phenylalanine: optimization of methotrexate prodrug for activation by carboxypeptidase A-monoclonal antibody conjugate.
Vitols KS; Haag-Zeino B; Baer T; Montejano YD; Huennekens FM
Cancer Res; 1995 Feb; 55(3):478-81. PubMed ID: 7834611
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo prodrug therapy of prostate cancer using anti-gamma-Sm-scFv/hCPA fusion protein.
Hao XK; Liu JY; Yue QH; Wu GJ; Bai YJ; Yin Y
Prostate; 2006 Jun; 66(8):858-66. PubMed ID: 16491483
[TBL] [Abstract][Full Text] [Related]
4. Specific tumour localisation of a huA33 antibody--carboxypeptidase A conjugate and activation of methotrexate-phenylalanine.
Deckert PM; Bornmann WG; Ritter G; Williams C; Franke J; Keilholz U; Thiel E; Old LJ; Bertino JR; Welt S
Int J Oncol; 2004 May; 24(5):1289-95. PubMed ID: 15067353
[TBL] [Abstract][Full Text] [Related]
5. Expression of endogenously activated secreted or cell surface carboxypeptidase A sensitizes tumor cells to methotrexate-alpha-peptide prodrugs.
Hamstra DA; Pagé M; Maybaum J; Rehemtulla A
Cancer Res; 2000 Feb; 60(3):657-65. PubMed ID: 10676650
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, cleavage profile, and antitumor efficacy of an albumin-binding prodrug of methotrexate that is cleaved by plasmin and cathepsin B.
Warnecke A; Fichtner I; Sass G; Kratz F
Arch Pharm (Weinheim); 2007 Aug; 340(8):389-95. PubMed ID: 17628030
[TBL] [Abstract][Full Text] [Related]
7. Development of methotrexate alpha-peptides as prodrugs for activation by enzyme-monoclonal antibody conjugates.
Huennekens FM
Adv Enzyme Regul; 1997; 37():77-92. PubMed ID: 9381987
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and preliminary in vitro screening of lipophilic alpha, gamma-bis(amides) as potential prodrugs of methotrexate.
Pignatello R; Sorrenti V; Spampinato G; Pecora T; Panico A; Di Giacomo C; Fresta M; Vanella A; Puglisi G
Anticancer Drug Des; 1996 Apr; 11(3):253-64. PubMed ID: 8663912
[TBL] [Abstract][Full Text] [Related]
9. Toward antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1 and novel in vivo stable prodrugs of methotrexate.
Smith GK; Banks S; Blumenkopf TA; Cory M; Humphreys J; Laethem RM; Miller J; Moxham CP; Mullin R; Ray PH; Walton LM; Wolfe LA
J Biol Chem; 1997 Jun; 272(25):15804-16. PubMed ID: 9188478
[TBL] [Abstract][Full Text] [Related]
10. Carboxypeptidase-mediated release of methotrexate from methotrexate alpha-peptides.
Kuefner U; Lohrmann U; Montejano YD; Vitols KS; Huennekens FM
Biochemistry; 1989 Mar; 28(5):2288-97. PubMed ID: 2719954
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and metabolism of the methotrexate metabolite 2, 4-diamino-N(10)-methylpteroic acid.
Widemann BC; Sung E; Anderson L; Salzer WL; Balis FM; Monitjo KS; McCully C; Hawkins M; Adamson PC
J Pharmacol Exp Ther; 2000 Sep; 294(3):894-901. PubMed ID: 10945838
[TBL] [Abstract][Full Text] [Related]
12. Occurrence and significance of diastereomers of methotrexate alpha-peptides.
Kuefner U; Esswein A; Lohrmann U; Montejano Y; Vitols KS; Huennekens FM
Biochemistry; 1990 Nov; 29(46):10540-5. PubMed ID: 2271663
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapeutic potential of methotrexate peptides.
Kuefner U; Lohrmann U; Montejano Y; Vitols KS; Huennekens FM
Adv Enzyme Regul; 1988; 27():3-13. PubMed ID: 3074629
[TBL] [Abstract][Full Text] [Related]
14. Synthesis of methotrexate prodrugs as an approach for drug targeting.
Perron M; Page M
Int J Oncol; 1994 Oct; 5(4):907-13. PubMed ID: 21559659
[TBL] [Abstract][Full Text] [Related]
15. TSPO Ligand-Methotrexate Prodrug Conjugates: Design, Synthesis, and Biological Evaluation.
Laquintana V; Denora N; Cutrignelli A; Perrone M; Iacobazzi RM; Annese C; Lopalco A; Lopedota AA; Franco M
Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27322261
[TBL] [Abstract][Full Text] [Related]
16. Alpha-monoamides of methotrexate as potential prodrugs.
Antonjuk DJ; Boadle DK; Cheung HT; Friedlander ML; Gregory PM; Tattersall MH
Arzneimittelforschung; 1989 Jan; 39(1):12-5. PubMed ID: 2719739
[TBL] [Abstract][Full Text] [Related]
17. Activation of methotrexate-alpha-alanine by carboxypeptidase A-monoclonal antibody conjugate.
Haenseler E; Esswein A; Vitols KS; Montejano Y; Mueller BM; Reisfeld RA; Huennekens FM
Biochemistry; 1992 Jan; 31(3):891-7. PubMed ID: 1731945
[TBL] [Abstract][Full Text] [Related]
18. Activation of methotrexate-phenylalanine by monoclonal antibody--carboxypeptidase A conjugate for the specific treatment of ovarian cancer in vitro.
Perron MJ; Page M
Br J Cancer; 1996 Feb; 73(3):281-7. PubMed ID: 8562331
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo antitumor activity of methotrexate conjugated to human serum albumin in human cancer cells.
Wosikowski K; Biedermann E; Rattel B; Breiter N; Jank P; Löser R; Jansen G; Peters GJ
Clin Cancer Res; 2003 May; 9(5):1917-26. PubMed ID: 12738750
[TBL] [Abstract][Full Text] [Related]
20. Overcoming methotrexate resistance in breast cancer tumour cells by the use of a new cell-penetrating peptide.
Lindgren M; Rosenthal-Aizman K; Saar K; Eiríksdóttir E; Jiang Y; Sassian M; Ostlund P; Hällbrink M; Langel U
Biochem Pharmacol; 2006 Feb; 71(4):416-25. PubMed ID: 16376307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
